ARS Pharmaceuticals: Climbing Neffy Sales And Global Expansion Could Re-Rate The Stock
Source: SeekingAlpha
2026-02-13 23:24:21 ET
...
Read the full article on Seeking Alpha
For further details see:
ARS Pharmaceuticals: Climbing Neffy Sales And Global Expansion Could Re-Rate The Stock
ARS Pharmaceuticals Inc.
NASDAQ: SPRY
SPRY Trading
-2.38% G/L:
$8.835 Last:
682,460 Volume:
$8.86 Open:
SPRY Latest News
March 09, 2026 06:00:00 am
ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization
SPRY Stock Data
$980,578,221
54,762,130
4.62%
62
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
